Annual Reports

 
Other

  • 6-K (Jun 4, 2013)
  • 6-K (May 3, 2013)
  • 6-K (May 2, 2013)
  • 6-K (Apr 10, 2013)
  • 424B5 (Apr 5, 2013)
  • 424B5 (Apr 3, 2013)
Sanofi-Aventis SA 6-K 2012

Documents found in this filing:

  1. 6-K
  2. Ex-99.1
  3. Ex-99.2
  4. Graphic
  5. Graphic
Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2012

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):            

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨             No  x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-            

 

 

 


In May 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

  

Description

Exhibit 99.1    Press release dated May 4, 2012: Combined General Shareholder Meeting of May 4, 2012
Exhibit 99.2    Press release dated May 17, 2012: ASCO Abstracts Highlight Late-stage Sanofi Oncology Pipeline

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: May 21, 2012     SANOFI  
    By   

/s/ John Felitti

 
     

Name: John Felitti

 
     

Title:   Associate Vice President,

            Corporate Law, Financial &

            Securities Law

 

 

3


Exhibit Index

 

Exhibit No.

  

Description

Exhibit 99.1    Press release dated May 4, 2012: Combined General Shareholder Meeting of May 4, 2012
Exhibit 99.2    Press release dated May 17, 2012: ASCO Abstracts Highlight Late-stage Sanofi Oncology Pipeline

 

4

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki